<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="102929">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01764529</url>
  </required_header>
  <id_info>
    <org_study_id>BVMC 6201</org_study_id>
    <secondary_id>U54NS065705</secondary_id>
    <nct_id>NCT01764529</nct_id>
  </id_info>
  <brief_title>Modifiers of Disease Severity in Cerebral Cavernous Malformations</brief_title>
  <official_title>Modifiers of Disease Severity and Progression in Cerebral Cavernous Malformations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of New Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Barrow Neurological Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Angioma Alliance</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of New Mexico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cerebral cavernous malformations (CCMs) are clusters of abnormal blood vessels in the brain
      and spine. CCMs can bleed and cause strokes, seizures, and headaches. CCMs are often caused
      by an inherited gene mutation (alteration) called CCM1. There is a wide range of disease
      severity even among family members with this disease, though the natural history has not
      been clearly described for this particular population.

      This study will examine factors that influence disease severity through the collection of
      blood samples, detailed medical histories, physical and neurological exam, and magnetic
      resonance imaging (MRI) of the brain in medical records. The specific goals of this study
      are to:

        1. establish a registry/database of familial CCM cases with detailed clinical data,

        2. perform genetic testing on participant blood samples to identify other genes that may
           influence the development and hemorrhage of CCM lesions, and

        3. determine lesion growth during the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is one of three projects participating in the Brain Vascular Malformation
      Consortium (BVMC) funded by the Office of Rare Diseases Research, which is part of the
      National Center for Advancing Translational Sciences (NCATS), and the National Institute of
      Neurological Disorders and Stroke (NINDS). The CCM project is a cross-sectional and
      longitudinal study of familial CCM1 patients. The study is currently in the second 5-year
      cycle. During the first 5 year cycle, the CCM project was focused on recruiting CCM1 cases
      with the common Hispanic mutation (CHM). For the second 5-year cycle, we are expanding
      recruitment to include not only CCM1-CHM cases, but also other CCM1 mutation carriers. We
      will collect clinical, genetic, imaging, treatment, and outcome data in participants, and
      follow the cohort over time to understand the natural history of this disease.

      For new study participants, you will be asked to:

        -  Give permission for study staff to access your medical records to collect clinical
           information and to obtain copies of MRI scans and reports

        -  Fill out a questionnaire about your quality of life, family history, and
           medical/surgical history

        -  Give a blood sample and/or saliva sample

        -  Give permission to store and use your CCM resected tissue for research (if undergoing
           surgery)

        -  Participate in annual follow-ups to update medical, surgical, and neurological
           information
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Total CCM lesion number per patient</measure>
    <time_frame>Baseline</time_frame>
    <description>The number of lesions (or cavernous angiomas) located in the brain will be counted by a neuroradiologist.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in lesion number</measure>
    <time_frame>Baseline, Follow up MRI</time_frame>
    <description>The number of lesions (or cavernous angiomas) counted on the baseline MRI will be compared to the number of lesions observed in the follow up study MRI. This will only be performed for the first 100 participants in the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin score per patient</measure>
    <time_frame>Baseline and annual assessment</time_frame>
    <description>The modified Rankin score will be assessed at baseline and at approximately one year intervals while remaining in study</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Cavernous Angioma, Familial</condition>
  <condition>Cerebral Cavernous Malformations</condition>
  <condition>Cerebral Cavernous Hemangioma</condition>
  <arm_group>
    <arm_group_label>CCM Participants</arm_group_label>
    <description>Have a confirmed diagnosis of CCM1 by DNA testing, or
Meet 2 of the 3 following criteria:
Clinical diagnosis of CCM
Evidence of multiple cavernous malformations on MRI
Someone in your immediate or extended family has a clinical diagnosis of CCM1</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      We collect and store saliva as well as whole blood for DNA and RNA extraction. Brain
      cavernous malformation tissue will be collected and banked as available.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population includes individuals who carry the cerebral cavernous maformation
        type 1 mutations (CCM1), both symptomatic and asymptomatic.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a confirmed diagnosis of CCM1 by DNA testing, or

          -  Meet 2 of the 3 following criteria:

          -  -Clinical diagnosis of CCM

          -  -Evidence of multiple cavernous malformations on MRI

          -  -Someone in your immediate or extended family has a clinical diagnosis of CCM1

        Exclusion Criteria:

          -  Incarceration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leslie Morrison, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of New Mexico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Blaine Hart, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of New Mexico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helen Kim, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amy Akers, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Angioma Alliance</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph Zabramski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barrow Neurological Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leslie A Morrison, MD</last_name>
    <phone>505-272-3194</phone>
    <email>lmorrison@salud.unm.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mary R Bartlett, BS</last_name>
    <phone>505 272-3194</phone>
    <email>MaryBartlett@salud.unm.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Barrow Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Harrigan</last_name>
      <phone>602-406-3465</phone>
      <email>mary.harrigan@dignityhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Guo</last_name>
      <phone>415-502-2224</phone>
      <email>diana.guo@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Health Sciences Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslie Morrison, MD</last_name>
      <phone>505-272-3194</phone>
      <email>lmorrison@salud.unm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mary R Bartlett, BS</last_name>
      <phone>505272-3194</phone>
      <email>marybartlett@salud.unm.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Leslie Morrison, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Blaine Hart, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Angioma Alliance</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy L Akers, PhD</last_name>
      <phone>757-818-0403</phone>
      <email>Amy.Akers@angioma.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.angiomaalliance.org/</url>
    <description>Angioma Alliance is an organization by and for those affected by cavernous angiomas and their loved ones, health professionals, and researchers.</description>
  </link>
  <reference>
    <citation>Choquet H, Pawlikowska L, Nelson J, McCulloch CE, Akers A, Baca B, Khan Y, Hart B, Morrison L, Kim H; Brain Vascular Malformation Consortium (BVMC) Study.. Polymorphisms in inflammatory and immune response genes associated with cerebral cavernous malformation type 1 severity. Cerebrovasc Dis. 2014;38(6):433-40. doi: 10.1159/000369200. Epub 2014 Dec 3.</citation>
    <PMID>25472749</PMID>
  </reference>
  <reference>
    <citation>Choquet H, Nelson J, Pawlikowska L, McCulloch CE, Akers A, Baca B, Khan Y, Hart B, Morrison L, Kim H. Association of cardiovascular risk factors with disease severity in cerebral cavernous malformation type 1 subjects with the common Hispanic mutation. Cerebrovasc Dis. 2014;37(1):57-63. doi: 10.1159/000356839. Epub 2013 Dec 21.</citation>
    <PMID>24401931</PMID>
  </reference>
  <reference>
    <citation>Golden M, Saeidi S, Liem B, Marchand E, Morrison L, Hart B. Sensitivity of patients with familial cerebral cavernous malformations to therapeutic radiation. J Med Imaging Radiat Oncol. 2015 Feb;59(1):134-6. doi: 10.1111/1754-9485.12269. Epub 2015 Jan 7.</citation>
    <PMID>25565562</PMID>
  </reference>
  <reference>
    <citation>Hart BL, Taheri S, Rosenberg GA, Morrison LA. Dynamic contrast-enhanced MRI evaluation of cerebral cavernous malformations. Transl Stroke Res. 2013 Oct;4(5):500-6. doi: 10.1007/s12975-013-0285-y. Epub 2013 Sep 21.</citation>
    <PMID>24323376</PMID>
  </reference>
  <reference>
    <citation>Akers AL, Ball KL, Clancy M, Comi AM, Faughnan ME, Gopal-Srivastava R, Jacobs TP, Kim H, Krischer J, Marchuk DA, McCulloch CE, Morrison L, Moses M, Moy CS, Pawlikowska L, Young WL. Brain Vascular Malformation Consortium: Overview, Progress and Future Directions. J Rare Disord. 2013 Apr 1;1(1):5.</citation>
    <PMID>25221778</PMID>
  </reference>
  <reference>
    <citation>Petersen TA, Morrison LA, Schrader RM, Hart BL. Familial versus sporadic cavernous malformations: differences in developmental venous anomaly association and lesion phenotype. AJNR Am J Neuroradiol. 2010 Feb;31(2):377-82. doi: 10.3174/ajnr.A1822. Epub 2009 Oct 15.</citation>
    <PMID>19833796</PMID>
  </reference>
  <reference>
    <citation>Choquet H, Trapani E, Goitre L, Trabalzini L, Akers A, Fontanella M, Hart BL, Morrison LA, Pawlikowska L, Kim H, Retta SF. Cytochrome P450 and matrix metalloproteinase genetic modifiers of disease severity in Cerebral Cavernous Malformation type 1. Free Radic Biol Med. 2016 Mar;92:100-9. doi: 10.1016/j.freeradbiomed.2016.01.008. Epub 2016 Jan 19.</citation>
    <PMID>26795600</PMID>
  </reference>
  <reference>
    <citation>Golden MJ, Morrison LA, Kim H, Hart BL. Increased number of white matter lesions in patients with familial cerebral cavernous malformations. AJNR Am J Neuroradiol. 2015 May;36(5):899-903. doi: 10.3174/ajnr.A4200. Epub 2015 Jan 2.</citation>
    <PMID>25556204</PMID>
  </reference>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 2, 2016</lastchanged_date>
  <firstreceived_date>January 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of New Mexico</investigator_affiliation>
    <investigator_full_name>Leslie Morrison</investigator_full_name>
    <investigator_title>Co-Leader</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Congenital Abnormalities</mesh_term>
    <mesh_term>Hemangioma</mesh_term>
    <mesh_term>Hemangioma, Cavernous, Central Nervous System</mesh_term>
    <mesh_term>Hemangioma, Cavernous</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Available data will be released to the Rare Diseases Clinical Research Network repository and will become available to the scientific community one year after publication of planned analyses, or after a period of 5 years from the date when the data were collected, whichever comes first</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
